drugset / Trial / NCT00005858
LMB-9 Immunotoxin in Treating Patients With Advanced Colon, Breast, Non-small Cell Lung, Bladder, Pancreatic, or Ovarian Cancer
Phase 1
Completed
25 enrolled
University of Maryland, Baltimore
National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment
Summary
Phase I trial to study the effectiveness of LMB-9 immunotoxin in treating patients who have advanced colon, breast, non-small cell lung, bladder, pancreatic, or ovarian cancer. The LMB-9 immunotoxin can locate tumor cells and kill them without harming normal cells.
Timeline
- Start
- 2000-04
- Primary completion
- 2003-12
- Completion
- 2003-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LMB-9 immunotoxin | Protein / enzyme biologic | — | Intravenous |